The Broad Institute, Inc.;Bayer Pharma AG;Dana-Farber Cancer Institute, Inc.
发明人:
Luc De Waal,Matthew Meyerson,Heidi Greulich,Monica Schenone,Alex Burgin,Xiaoyun Wu,Ulrike Sack
申请号：
US15752130
公开号：
US20180235961A1
申请日:
2016.08.12
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
